

12. BÖLÜM

Halüsinojen Etkili Maddeler

Melike AYDOĞDU¹
Ömer DEMİR²

Genel Bilgi, Kısa Tarihçe ve Güncel Klinik/Yasal Durumu

Halüsinojenler, algıyı, ruh halini ve bir dizi bilişsel süreci güçlü bir şekilde değiştiren psikoaktif maddeler olarak tanımlanmaktadır. Bu sınıfta yer alan farmakolojik olarak aktif maddelerin ortak özelliği, bilinci sıklıkla dramatik, öngörülemeyen şekillerde değiştirmeleridir ve yüksek dozlarda deliryum, gerçek halüsinasyonlar, gerçeklikle temas kaybı ve bazı durumlarda ölüme neden olabilmeleridir. Bu grubu tanımlamak için, “halüsinojen”, Yunanca içindeki tanrı anlamına gelen “entheogen”, popüler medyada ve internet sitelerinde kullanımı popüler olan “psikedelik”, deneysel psikoz araştırmaları için “psikotomimetik” kavramları yaygın olarak kullanılmaktadır (1).

Tarih boyunca insanlar halüsinojenleri birçok farklı amaç için kullanmıştır (2). Bu halüsinojen etkisi olan bitkileri ruhsal bağlantılar, halüsinasyonlar, coşkuyu ve en yüksek performansı deneyimlemek için kullandıkları bilinmektedir. Yapılan arkeolojik ve tarih çalışmalarında, tüm kıtalardan insanların olumsuz sonuçlarından bağımsız olarak bu bitkileri kullandıkları belirlenmiştir. M.Ö. 4000 yılına kadar uzanan belirli kültürlerin ve dinlerin şekillenmesinde halüsinojenlerin büyük ölçüde etkili olduğu düşünülmektedir. M.Ö. 4000-3500'lü yıllarda psilosibinin ilk mağara resimleri Avrupa ve Kuzey Afrika'da bulunmuş,

¹ Dr. Kimyager, Ege Üniversitesi Madde Bağımlılığı, Toksikoloji ve İlaç Bilimleri Enstitüsü, kim.melike.gungor@gmail.com

² Uzm. Dr, SBU İzmir Tepecik eğitim ve Araştırma Hastanesi, dromerdemir@gmail.com

Halüsinojenlerle ilgili bu bölümde yer almayan diğer bazı bilgilere “Youtube” videomuz aracılığıyla ulaşabilirsiniz.

https://youtu.be/UlgAO_JDPHQ



SCAN ME!

KAYNAKLAR

1. Nichols DE. Hallucinogens. *Pharmacology and Therapeutics*. 2004;101(2): 131–181. doi:10.1016/j.pharmthera.2003.11.002
2. Araújo AM, Carvalho F, Bastos M de L, et al. The hallucinogenic world of tryptamines: an updated review. *Archives of Toxicology*. Springer Berlin Heidelberg; 2015;89(8): 1151–1173. doi:10.1007/s00204-015-1513-x
3. Garcia-Romeu A, Kersgaard B, Addy PH. Clinical applications of hallucinogens: A review. *Experimental and Clinical Psychopharmacology*. 2016;24(4): 229–268. doi:10.1037/pha0000084
4. Luethi D, Liechti ME. *Designer drugs: mechanism of action and adverse effects*. [Online] *Archives of Toxicology*. Springer Berlin Heidelberg; 2020. 1085–1133 p. doi:10.1007/s00204-020-02693-7
5. Araújo AM, Carvalho F, Bastos M de L, et al. The hallucinogenic world of tryptamines: an updated review. *Archives of Toxicology*. Springer Berlin Heidelberg; 2015;89(8): 1151–1173. doi:10.1007/s00204-015-1513-x
6. *Lysergic acid diethylamide*. [Online] <http://www.chemspider.com/Chemical-Structure.5558.html>
7. *Hallucinogenic mushrooms drug profile*. [Online] https://www.emcdda.europa.eu/publications/drug-profiles/hallucinogenic-mushrooms_en
8. EMCDDA. *Lysergide (LSD) drug profile*. [Online] https://www.emcdda.europa.eu/publications/drug-profiles/lsd_en
9. Marinho PA, Leite EMA. Quantification of LSD in illicit samples by high performance liquid chromatography. *Brazilian Journal of Pharmaceutical Sciences*. 2010;46(4): 695–703. doi:10.1590/S1984-82502010000400011
10. Dolder PC, Schmid Y, Steuer AE, et al. Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects. *Clinical Pharmacokinetics*. Springer International Publishing; 2017;56(10): 1219–1230. doi:10.1007/s40262-017-0513-9
11. Libânio Osório Marta RF. Metabolism of lysergic acid diethylamide (LSD): an update. *Drug Metabolism Reviews*. Taylor & Francis; 2019;51(3): 378–387. doi:10.1080/03602532.2019.1638931
12. Klock JC, Boerner U, Becker CE. Coma, hyperthermia and bleeding associated with massive LSD overdose. A report of eight cases. *West J Med*. 1974;120(3): 183–188. <http://www.ncbi.nlm.nih.gov/pubmed/4816396>

13. Nichols DE, Grob CS. Is LSD toxic? *Forensic Science International*. 2018;284: 141–145. doi:10.1016/j.forsciint.2018.01.006
14. Grobosch T, Lemm-Ahlers U. Immunoassay screening of lysergic acid diethylamide (LSD) and its confirmation by HPLC and fluorescence detection following LSD ImmunElute extraction. *Journal of Analytical Toxicology*. 2002;26(3): 181–186. doi:10.1093/jat/26.3.181
15. Gaulier J michel, Maublanc J, Lamballais F, et al. LSD in pubic hair in a fatality. *Forensic Science International*. 2012;218(1–3): 25–27. doi:10.1016/j.forsciint.2011.10.021
16. Bruhn JG, De Smet PAGM, El-Seedi HR, et al. Mescaline use for 5700 years. *The Lancet*. 2002;359(25): 2002–2002.
17. Meuninck J. *Poisonous and Psychoactive Plants*.. 1st ed. Globe Pequot Press. Morris Book Publishing; 2014.
18. Dinis-Oliveira RJ, Pereira CL, da Silva DD. Pharmacokinetic and Pharmacodynamic Aspects of Peyote and Mescaline: Clinical and Forensic Repercussions. *Current Molecular Pharmacology*. 2018;12(3): 184–194. doi:10.2174/1874467211666181010154139
19. Cassels BK, Sáez-Briones P. Dark Classics in Chemical Neuroscience: Mescaline. *ACS Chemical Neuroscience*. 2018;9(10): 2448–2458. doi:10.1021/acchemneuro.8b00215
20. Dinis-Oliveira RJ, Pereira CL, da Silva DD, et al. Urine mescaline screening with a biochip array immunoassay and quantification by gas chromatography-mass spectrometry. *The Lancet*. 2020;37(1): 372–375. doi:10.1086/710634
21. Longo CM, Musah RA. An Efficient Ambient Ionization Mass Spectrometric Approach to Detection and Quantification of the Mescaline Content of Commonly Abused Cacti from the Echinopsis Genus. *Journal of Forensic Sciences*. 2020;65(1): 61–66. doi:10.1111/1556-4029.14134
22. Dinis-Oliveira RJ. Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance. *Drug Metabolism Reviews*. 2017;49(1): 84–91. doi:10.1080/03602532.2016.1278228
23. *Psilocybine*. [Online] <https://pubchem.ncbi.nlm.nih.gov/compound/Psilocybine>
24. Dasgupta A. Abuse of magic mushroom, peyote cactus, LSD, khat, and volatiles. *Critical Issues in Alcohol and Drugs of Abuse Testing*. Second Edi. Elsevier Inc.; 2019. p. 477–494. doi:10.1016/B978-0-12-815607-0.00033-2
25. Gartz J. *Magic Mushrooms Around the World A Scientific Journey Across Cultures and Time*. 1997; 133.
26. Martin R, Schürenkamp J, Pfeiffer H, et al. A validated method for quantitation of psilocin in plasma by LC-MS/MS and study of stability. *International Journal of Legal Medicine*. 2012;126(6): 845–849. doi:10.1007/s00414-011-0652-8
27. Tiscione NB, Miller MI. Psilocin identified in a DUID investigation. *Journal of Analytical Toxicology*. 2006;30(5): 342–345. doi:10.1093/jat/30.5.342
28. UNODC. *Phencyclidine-type substances*. [Online] <https://www.unodc.org/LSS/SubstanceGroup/Details/6bf165ed-82e7-47e0-9eaa-daacc42d99cd>
29. Bertron JL, Seto M, Lindsley CW. DARK Classics in Chemical Neuroscience: Phencyclidine (PCP). *ACS Chemical Neuroscience*. 2018;9(10): 2459–2474. doi:10.1021/acchemneuro.8b00266
30. Dugan S, Bogema S, Schwartz RW, et al. Stability of drugs of abuse in urine samples stored at -20 degrees C. *J Anal Toxicol*. 1994;18(7): 391–396. <http://www.ncbi.nlm.nih.gov/pubmed/7861752>

31. Rengarajan A, Mullins ME. How often do false-positive phencyclidine urine screens occur with use of common medications? *Clinical Toxicology*. Clin Toxicol (Phila); 2013;51(6): 493–496. doi:10.3109/15563650.2013.801982
32. Budd R, Liu Y. Phencyclidine concentrations in postmortem body fluids and tissues. *Journal of toxicology. Clinical Toxicology*. 1982;19(8): 843–850.
33. Misra AL, Pontani RB, Bartolomeo J. Persistence of phencyclidine (PCP) and metabolites in brain and adipose tissue and implications for long-lasting behavioural effects. *Res Commun Chem Pathol Pharmacol*. 1979;24(3): 431–445. <http://www.ncbi.nlm.nih.gov/pubmed/451333>
34. *Dimetiltriptamin*. [Online] <https://eksisozluk.com/dimetiltriptamin--116693>
35. Dean JG. Indoethylamine-N-methyltransferase polymorphisms: Genetic and biochemical approaches for study of endogenous N, N-dimethyltryptamine. *Frontiers in Neuroscience*. 2018;12(APR). doi:10.3389/fnins.2018.00232
36. Vitale AA, Pomilio AB, Cañellas CO, et al. In vivo long-term kinetics of radiolabeled N,N-dimethyltryptamine and tryptamine. *Journal of Nuclear Medicine*. 2011;52(6): 970–977. doi:10.2967/jnumed.110.083246
37. Santos RG dos, Bouso JC, Hallak JEC. Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies. *Therapeutic Advances in Psychopharmacology Review*. 2017;7(4): 141–157. doi://doi.org/10.1177/2045125316689030 DOI: 10.1177/ <https://doi.org/10.1177/2045125>
38. Cameron LP, Olson DE. Dark Classics in Chemical Neuroscience: N, N-Dimethyltryptamine (DMT). *ACS Chemical Neuroscience*. 2018;9(10): 2344–2357. doi:10.1021/acschemneuro.8b00101
39. *Effects of Dimethyltryptamine in Healthy Subjects (DMT)*. [Online] <https://clinicaltrials.gov/ct2/show/record/NCT04353024>
40. Sassano-Higgins S, Baron D, Juarez G, et al. A Review of Ketamine Abuse and Diversion. *Depression and Anxiety*. 2016;33(8): 718–727. doi:10.1002/da.22536
41. Grant IS, Nimmo WS, Clements JA. Pharmacokinetics and analgesic effects of I.M. and oral ketamine. *British Journal of Anaesthesia*. British Journal of Anaesthesia; 1981;53(8): 805–810. doi:10.1093/bja/53.8.805
42. Grant IS, Nimmo WS, Mcnicol LR, et al. Ketamine disposition in children and adults. *British Journal of Anaesthesia*. British Journal of Anaesthesia; 1983;55(11): 1107–1111. doi:10.1093/bja/55.11.1107
43. Hernández-Alvarado RB, Madariaga-Mazón A, Ortega A, et al. DARK Classics in Chemical Neuroscience: Salvinorin A. *ACS Chemical Neuroscience*. 2020;11(23): 3979–3992. doi:10.1021/acschemneuro.0c00608
44. Turner DM. Salvinorin - The Psychedelic Essence of Salvia Divinorum. *Essence*. 2004; 1–42.
45. Roach JJ, Shenvi RA. A review of salvinorin analogs and their kappa-opioid receptor activity. *Bioorganic and Medicinal Chemistry Letters*. 2018;28(9): 1436–1445. doi:10.1016/j.bmcl.2018.03.029
46. Socała K, Doboszewska U, Wlaź P. Salvinorin a does not affect seizure threshold in mice. *Molecules*. 2020;25(5). doi:10.3390/molecules25051204
47. Medana C, Massolino C, Pazzi M, et al. Determination of salvinorins and divinorins in Salvia divinorum leaves by liquid chromatography/multistage mass spectrometry. *Rapid Commun Mass Spectrom*. 2006;20(2): 131–136.

48. Barnes BB, Snow NH. Analysis of Salvinorin A in plants, water, and urine using solid-phase microextraction-comprehensive two-dimensional gas chromatography-time of flight mass spectrometry. *J Chromatogr A*. 2012;1226: 110–115. doi:10.1016/j.chroma.2011.09.056
49. El-Khoury J, Baroud E. Case series: Salvia divinorum as a potential addictive hallucinogen. *American Journal on Addictions*. 2018;27(3): 163–165. doi:10.1111/ajad.12715
50. Gaire BP, Subedi L. A review on the pharmacological and toxicological aspects of Datura stramonium L. *Journal of Chinese Integrative Medicine*. Journal of Integrative Medicine Editorial Office. E-edition published by Elsevier (Singapore) Pte Ltd. All rights reserved.; 2013;11(2): 73–79. doi:10.3736/jintegrmed2013016
51. Amini M, Khosrojerdi H, Afshari R. Acute Datura Stramonium poisoning in East of Iran - a case series. *Avicenna journal of phytomedicine*. 2012;2(2): 86–89. doi:10.22038/ajp.2012.37
52. Suzuki J, Dekker MA, Valenti ES, et al. Toxicities Associated With NBOMe Ingestion-A Novel Class of Potent Hallucinogens: A Review of the Literature. *Psychosomatics*. Elsevier; 2015;56(2): 129–139. doi:10.1016/j.psym.2014.11.002
53. Altuncı YA, Aydođdu M, Açıkgöz E, et al. New Psychoactive Substance 5-MeO-MIPT In vivo Acute Toxicity and Hystotoxicological Study. *Balkan Medical Journal*. 2020; doi:10.4274/balkanmedj.galenos.2020.2019.11.68